Table 3 Sensitivity analyses of the HER2DX risk score for RFS and OS in patients with node-negative disease treated with trastuzumab alone
Outcome | Time (yrs) | Low-risk estimate (95% CI) | High-risk estimate (95% CI) | HR (95% CI) |
|---|---|---|---|---|
RFS | 5 | 88.7 (80.5–97.7) | 68.6 (44.5–100.0) | 0.33 (0.1–1.3) |
6 | 86.5 (77.6–96.4) | 68.6 (44.5–100.0) | 0.36 (0.1–1.5) | |
7 | 82.2 (72.2–93.5) | 57.1 (32.6–100.0) | 0.35 (0.1–1.2) | |
8 | 82.2 (72.2–93.5) | 57.1 (32.6–100.0) | 0.35 (0.1–1.2) | |
9 | 76.2 (64.4–90.2) | 57.1 (32.6–100.0) | 0.42 (0.1–1.3) | |
10 | 76.2 (64.4–90.2) | 57.1 (32.6–100.0) | 0.42 (0.1–1.3) | |
OS | 5 | 96.4 (91.6–100.0) | 80.0 (58.7–100.0) | 0.28 (0.1–0.9) |
6 | 94.4 (88.5–100.0) | 80.0 (58.7–100.0) | 0.25 (0.0–1.5) | |
7 | 92.5 (85.6–99.9) | 68.6 (44.5–100.0) | 0.21 (0.1–0.9) | |
8 | 92.5 (85.6–99.9) | 68.6 (44.5–100.0) | 0.21 (0.1–0.9) | |
9 | 86.9 (77.3–97.7) | 68.6 (44.5–100.0) | 0.31 (0.1–1.2) | |
10 | 86.9 (77.3–97.7) | 45.7 (18.4–100.0) | 0.23 (0.1–0.8) |
